
About Nkure Therapeutics Private Limited
Data last updated:
Nkure Therapeutics Private Limited is a private limited company based in Bangalore, Karnataka, India, recognised as a startup by DPIIT. It operates in the biotechnology segment of the life sciences sector. It was incorporated on 11 February 2022.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U73100KA2022PTC157838. Its GSTIN is 29AAICN0766H1Z6 (Karnataka).
The company has an authorised share capital of ₹4.5 Cr and a paid-up capital of ₹3.07 Cr. It is led by directors including Ashok Nana Vohra and Mahendra Surendra Rao.
Its last annual general meeting (AGM) was held on 18 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Desk No. 15 – L No. 14 Bhattarahalli Old Madras Road Kr Puram, Bangalore, Karnataka, India – 560049.
As per the financials filed for FY 2026, the company reported a revenue of ₹1.69 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net loss of ₹7.8 Cr (net margin -462.5%) and EBITDA of -₹7.71 Cr (EBITDA margin -456.9%).
The company is associated with 1 brand: NKure Theraputics. The company has 5 deals on record (2 funding rounds, 2 secondary share transfers, 1 convertible or debt financing), with disclosed funding of ₹2.49 Cr; the latest was in April 2023. The company has 3 MSME Form 1 returns on record between 2022 and 2023, listing 16 overdue payments to 2 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website nkure.com.
Company details
Recognitions & Rankings of Nkure Therapeutics
Contact details
Nkure Therapeutics Private Limited's registered office is in Bangalore, Karnataka. Its website is nkure.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressDesk No. 15 – L No. 14 Bhattarahalli Old Madras Road Kr Puram, Bangalore, Karnataka, India – 560049
- IndustryLife Sciences, Biotechnology
To see the full contact details of Nkure Therapeutics Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Nkure Therapeutics operates one associated brand: NKure Theraputics. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Developer of NK cell therapies for the treatment of cancer | nkure.com |
Business activity
The main business activity of Nkure Therapeutics is professional, scientific and technical activities. In detail, this covers scientific research and development.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, scientific and technical activities | 72 | Scientific research and development |
To see the full business activity and turnover split of Nkure Therapeutics Private Limited, buy the company report.
Financials of Nkure Therapeutics Private Limited
FY 2026 filings availableNkure Therapeutics Private Limited reported revenue of ₹1.69 Cr (up 492% YoY) for FY 2026.
Compounded Annual Growth Rate (CAGR)
Revenue rose 492% in the latest year. EBITDA fell 42% in the latest year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹1.69 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹7.71 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹7.8 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -456.9% | ||||
| Net Profit Margin | -462.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Nkure Therapeutics Private Limited, buy the company report.
Board of directors of Nkure Therapeutics Private Limited
Nkure Therapeutics has 3 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ashok Nana Vohra Also directs: Bio-Combinator LLP, Escape Velocity Accelerator India LLP, Evoma Facilities (India) Private Limited and 3 more | Director | 11 Feb 2022 | 4 Years 9 Months | Current |
| Mahendra Surendra Rao Also directs: Eyestem Research Private Limited | Director | 04 Mar 2022 | 4 Years 8 Months | Current |
| Lalitkumar Manjunath Pai | Director | 01 Aug 2023 | 3 Years 3 Months | Current |
Auditor
Nkure Therapeutics Private Limited is audited by Dhirubhai Shah & Co LLP. for the financial year 2026.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Dhirubhai Shah & Co LLP. | FY 2026 | 102511W/W100298 |
Shareholding
The shareholding of Nkure Therapeutics Private Limited is on record for 4 financial years, the latest being FY 2026, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Foreign institutional investors (FII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Nkure Therapeutics Private Limited, buy the company report.
Deals & funding
Nkure Therapeutics Private Limited has 5 deals on record (2 funding rounds, 2 secondary share transfers, 1 convertible or debt financing), with disclosed funding of ₹2.49 Cr; the latest was in April 2023.
Deals on record (4 of 5)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2023 | Funding round · Pre-Series A | Undisclosed | Investors: Endiya Partners, Kotak Private Equity, an individual |
| Mar 2023 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Jun 2022 | Funding round | ₹1.24 Cr | Investors: 4 individuals |
| Mar 2022 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
To see the full deal history of Nkure Therapeutics Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Nkure Therapeutics Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
Nkure Therapeutics Private Limited has 3 MSME Form 1 returns on record between 2022 and 2023, listing 16 overdue payments to 2 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (2 of 2)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Nkure Therapeutics Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Nkure Therapeutics has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AAICN0766H1Z6 | Karnataka | Active | 13 May 2022 |
To see the full GST registrations and return filing status of Nkure Therapeutics Private Limited, buy the company report.
Recent activity
Nkure Therapeutics Private Limited has 6 board changes on record since 2022: 3 appointments and 3 cessations. The latest: Lalitkumar Manjunath Pai ceased to be Additional Director on 29 Sep 2023.
Frequently asked questions
Nkure Therapeutics is an active private limited company based in Bangalore, Karnataka, India. The company works in biotechnology, within the life sciences industry. It was incorporated on 11 February 2022 (4+ years old) and is registered under CIN U73100KA2022PTC157838.
Nkure Therapeutics has 3 current directors:
- Ashok Nana Vohra - Director
- Mahendra Surendra Rao - Director
- Lalitkumar Manjunath Pai - Director
The latest financial statements of Nkure Therapeutics on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 18 August 2025. Year-wise statements from FY 2022 are in the company report.
The GSTIN of Nkure Therapeutics is 29AAICN0766H1Z6, registered in Karnataka.
The CIN (Corporate Identification Number) of Nkure Therapeutics is U73100KA2022PTC157838. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Nkure Therapeutics was incorporated on 11 February 2022, making it 4+ years old. It is registered with the Registrar of Companies, Bangalore.
Nkure Therapeutics has 5 deals on record (2 funding rounds, 2 secondary share transfers, 1 convertible or debt financing), with disclosed funding of ₹2.49 Cr; the latest was in April 2023.
Lalitkumar Manjunath Pai ceased to be Additional Director on 29 Sep 2023. Mahendra Surendra Rao ceased to be Additional Director on 29 Sep 2023. Lalitkumar Manjunath Pai was appointed as Director on 01 Aug 2023. Nkure Therapeutics has 6 board changes on record in total.
Yes, Nkure Therapeutics is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).
Nkure Therapeutics has 3 MSME Form 1 returns on record between 2022 and 2023, listing 16 overdue payments to 2 micro and small suppliers. The latest return was filed on 28 Aug 2023.
Nkure Therapeutics can be reached through the website nkure.com. Its registered office is in Bangalore, Karnataka, India.

